scholarly journals The link between phenotype and fatty acid metabolism in advanced chronic kidney disease

2017 ◽  
Vol 32 (7) ◽  
pp. 1154-1166 ◽  
Author(s):  
Dan-Qian Chen ◽  
Hua Chen ◽  
Lin Chen ◽  
Nosratola D. Vaziri ◽  
Ming Wang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Metabolism ◽  
Acid Metabolism ◽  
Advanced Chronic Kidney Disease

scholarly journals Global Gene Expression Profiling in PPAR-γAgonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease

PPAR Research ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Daisuke Yoshihara ◽  
Masanori Kugita ◽  
Tamio Yamaguchi ◽  
Harold M. Aukema ◽  
Hiroki Kurahashi ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cell Cycle ◽  
Cell Proliferation ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Metabolism ◽  
Acid Metabolism ◽  
Interstitial Fibrosis ◽  
Global Gene Expression ◽  
Polycystic Kidney

Kidneys are enlarged by aberrant proliferation of tubule epithelial cells leading to the formation of numerous cysts, nephron loss, and interstitial fibrosis in polycystic kidney disease (PKD). Pioglitazone (PIO), a PPAR-γagonist, decreased cell proliferation, interstitial fibrosis, and inflammation, and ameliorated PKD progression in PCK rats (Am. J. Physiol.-Renal, 2011). To explore genetic mechanisms involved, changes in global gene expression were analyzed. By Gene Set Enrichment Analysis of 30655 genes, 13 of the top 20 downregulated gene ontology biological process gene sets and six of the top 20 curated gene set canonical pathways identified to be downregulated by PIOtreatment were related to cell cycle and proliferation, including EGF, PDGF and JNK pathways. Their relevant pathways were identified using the Kyoto Encyclopedia of Gene and Genomes database. Stearoyl-coenzyme A desaturase 1 is a key enzyme in fatty acid metabolism found in the top 5 genes downregulated by PIO treatment. Immunohistochemical analysis revealed that the gene product of this enzyme was highly expressed in PCK kidneys and decreased by PIO. These data show that PIO alters the expression of genes involved in cell cycle progression, cell proliferation, and fatty acid metabolism.

scholarly journals Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism

Metabolites ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 372
Author(s):  
Daiki Aomura ◽  
Makoto Harada ◽  
Yosuke Yamada ◽  
Takero Nakajima ◽  
Koji Hashimoto ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Metabolism ◽  
Acid Metabolism ◽  
Male Mice ◽  
Histological Findings ◽  
Tubular Injury ◽  
Wild Type ◽  
Wild Type Male ◽  
And Oxidative Stress

As classical agonists for peroxisomal proliferator-activated receptor alpha (PPARα), fibrates activate renal fatty acid metabolism (FAM) and provide renoprotection. However, fibrate prescription is limited in patients with kidney disease, since impaired urinary excretion of the drug causes serious adverse effects. Pemafibrate (PEM), a novel selective PPARα modulator, is mainly excreted in bile, and, thus, may be safe and effective in kidney disease patients. It remains unclear, however, whether PEM actually exhibits renoprotective properties. We investigated this issue using mice with fatty acid overload nephropathy (FAON). PEM (0.5 mg/kg body weight/day) or a vehicle was administered for 20 days to 13-week-old wild-type male mice, which were simultaneously injected with free fatty acid (FFA)-binding bovine serum albumin from day 7 to day 20 to induce FAON. All mice were sacrificed on day 20 for assessment of the renoprotective effect of PEM against FAON. PEM significantly attenuated the histological findings of tubular injury caused by FAON, increased the renal expressions of mRNA and proteins related to FAM, and decreased renal FFA content and oxidative stress. Taken together, PEM exhibits renoprotective effects through the activation and maintenance of renal FAM and represents a promising drug for kidney disease.

394-P: ROCK1/AMPK Axis Regulates the Development of Diabetic Kidney Disease via Modulation of Fatty Acid Metabolism

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 394-P
Author(s):  
YOSUKE NAGAI ◽  
KEIICHIRO MATOBA ◽  
KENSUKE SEKIGUCHI ◽  
RIKAKO UKICHI ◽  
YUSUKE TAKEDA ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Metabolism ◽  
Diabetic Kidney Disease ◽  
Acid Metabolism ◽  
Diabetic Kidney

Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients

2017 ◽  
Vol 13 (11) ◽  
pp. 2392-2400 ◽  
Author(s):  
Ling Li ◽  
Chengshi Wang ◽  
Hongliu Yang ◽  
Shuyun Liu ◽  
Yanrong Lu ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Early Intervention ◽  
Kidney Disease ◽  
Fatty Acid Metabolism ◽  
Diabetic Kidney Disease ◽  
Acid Metabolism ◽  
Diabetic Kidney

Diabetic kidney disease (DKD) is the leading cause of ESRD; however, early intervention can greatly prevent the progression of DKD; thus, sensitive biomarkers for DKD are still required.

469-P: ROCK1/AMPK Axis Regulates the Development of Diabetic Kidney Disease via Modulation of Fatty Acid Metabolism

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 469-P
Author(s):  
YOSUKE NAGAI ◽  
KEIICHIRO MATOBA ◽  
YUSUKE TAKEDA ◽  
TOMOYO AKAMINE ◽  
DAIJI KAWANAMI ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Metabolism ◽  
Diabetic Kidney Disease ◽  
Acid Metabolism ◽  
Diabetic Kidney
Sign in / Sign up

Export Citation Format

Share Document